Humulin Nph

Humulin Nph is a recombinant human insulin (Insulin human, rDNA) supplied as an injectable solution for subcutaneous or intramuscular administration. The product’s strength is not specified in the source data, and it is marketed in the European Union as a prescription‑only medication for managing blood glucose levels in diabetes mellitus.

Humulin Nph is used as a basal insulin to provide long‑acting glucose control in diabetes management. It is appropriate for patients who require steady insulin coverage throughout the day and night.

- Treatment of type 1 diabetes mellitus as part of a basal‑bolus regimen. - Treatment of type 2 diabetes mellitus when oral agents are insufficient. - Adjunct therapy with rapid‑acting insulin analogues for intensive insulin therapy. - Use in combination with oral antidiabetic agents to achieve target glycaemic control. - Suitable for patients requiring a predictable, intermediate‑acting insulin profile.

Humulin Nph may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious potential effects.

Common: - Hypoglycaemia (low blood glucose) - Injection site redness, swelling, or itching - Lipodystrophy at injection sites - Weight gain - Mild nausea

Serious: - Severe hypoglycaemia with loss of consciousness - Allergic reactions such as urticaria or angioedema - Anaphylaxis - Persistent hyperglycaemia due to insulin resistance

Before initiating Humulin Nph, consider the following safety points.

- Assess renal and hepatic function, as impairment may alter insulin requirements. - Monitor blood glucose regularly to avoid hypoglycaemia, especially during dose adjustments. - Use caution in pregnant or breastfeeding women; consult a healthcare professional. - Evaluate for any history of allergic reactions to insulin or excipients. - Adjust doses during periods of illness, surgery, or changes in physical activity. - Educate patients on proper injection technique to reduce lipodystrophy risk.

Humulin Nph can interact with several medications, affecting its efficacy or safety.

Avoid: - Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycaemia. - High‑dose beta‑blockers that mask hypoglycaemia symptoms. - Certain oral antidiabetic agents (e.g., sulfonylureas) that increase hypoglycaemia risk.

Use with caution: - Corticosteroids, which may raise blood glucose and require higher insulin doses. - Diuretics, especially thiazides, that can affect glucose tolerance. - MAO‑B inhibitors, which may potentiate hypoglycaemic episodes. - Alcohol, as it can cause unpredictable glucose fluctuations.